The combination of ADCs with PD-1/PD-L1 inhibitors is poised to become a new treatment paradigm for SCLC, with the DLL3-targeted ADC ZL-1310 now in clinical trials alongside atezolizumab (NCT06179069). This evidence concerns the gene PDCD1 and small cell lung carcinoma.